MET and cancer: Point mutations activating and amplifying c-MET expression, and c-MET/HGF co-expression, have been observed in many human cancers, including GC [10,11,12]; high-level HGF expression and c-MET overexpression are often associated with poor clinical outcomes, thus more aggressive disease, increased tumor metastasis, and reduced survival [13,14,15].